GenSci133 Injection Gets Clinical Trial Approval for Osteoporosis Treatment
GenSci133, an investigational injection developed by Changchun High-tech's subsidiary Jinsai Pharmaceutical, has received clinical trial approval from China's National Medical Products Administration. The drug, a parathyroid hormone analog and RANKL antibody fusion protein, is intended for osteoporosis treatment and will be administered subcutaneously every three to six months.
Changchun High-tech's controlling subsidiary Jinsai Pharmaceutical has received the Drug Clinical Trial Approval Notice issued by China's National Medical Products Administration, approving the company's application for a domestic production drug registration clinical trial for GenSci133 injection. The application was publicly announced on September 4, 2026, marking the drug's entry into the clinical trial stage.
GenSci133 injection is a parathyroid hormone analog and receptor activator of nuclear factor kappa-B ligand antibody fusion protein independently developed by Jinsai Pharmaceutical. It is classified as a Class 1 therapeutic biological product and is intended for the treatment of osteoporosis. The drug is designed for subcutaneous administration once every three to six months, with the specific dosing frequency to be determined based on subsequent clinical trial results.